In recent years, Immune checkpoint inhibitors (ICIs) that target programmed cell death protein 1(PD-1) or programmed cell death ligand 1 (PD-L1) have shown outstanding performance in esophageal cancer therapy, which enhances the anti-tumor activity across esophageal cancer. The gene discussed is PDCD1; the disease is neoplasm.